2021/08/03
State-of-the-art facility significantly enhances WuXi STA's drug product capacity in Europe while better enabling global customers
Read more2021/06/28
WILMINGTON, Del. (June 28, 2021) — WuXi STA and Delaware Prosperity Partnership today announced that WuXi STA, a leading Contract Development and Manufacturing Organization (CDMO), will build a new pharmaceutical manufacturing campus in Middletown, Delaware. The state-of-the-art WuXi STA Middletown Site, which is expected to open in 2024 and be its first on the East Coast, will be located at 1091 Industrial Drive in Middletown Business Center and aims to bring about 500 new full-time jobs to Delaware by 2026.
Read more2021/04/29
(SHANGHAI, April 29, 2021) — WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients, announces its unaudited financial results for the First-Quarter of 2021 (“Reporting Period”).
Read more2021/03/30
(SHANGHAI, March 30, 2021) — WuXi AppTec (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients, announces its audited annual results for the year ended December 31, 2020 (“Reporting Period”).
Read more2021/03/02
PHILADELPHIA and OXFORD, March 2, 2021 - WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries, today announced that it has completed the acquisition of OXGENE, a pioneering United Kingdom-based contract research and development organization that designs and develops scalable gene therapy technologies. This acquisition enables WuXi AppTec to offer its customers end-to-end support in the creation and development of cutting-edge cell and gene therapies for patients in need worldwide.
Read more